Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmather Holdings Ltd C.PHRM

Alternate Symbol(s):  PHRRF

PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases.


CSE:PHRM - Post by User

Post by TheLandedEagleson Apr 27, 2024 9:10pm
286 Views
Post# 36011296

High Impact...multi-bagger!!!!

High Impact...multi-bagger!!!!Investors looking for Big Rewards with minimal risk at this late stage of a FDA imminent approval,...needs to have a locked-in share position in PharmaTher....Hugh upside very soon.
Look to the company's latest February 2024 Presentation on their web-site. Hold and Accumulate, at these extremely low prices....All time high was $1.20/share in 2021, raised $10mm in August 2021 at .66 cents/share with warrants expiring in 2026 at .80 cents exercise price, and that will bring in more than $6mm in cash and adding in their current $4mm cash, gives them a total of $10mm to finance its marketing/Sales and distribution for its approved FDA KETRAX....NO NEED FOR ANY FINANCING!!! Preventing share dilution....great financial position ...
<< Previous
Bullboard Posts
Next >>